In 2021, Harbour Antibodies initiated a case claiming that Amgen and its subsidiary, Teneobio, had violated patents safeguarding Harbour's revolutionary antibody discovery platform. Following a trial in Delaware, the jury determined that the infringement was deliberate, upheld the validity of the patent, and granted Harbour Antibodies the full amount of $20.2 million in damages.